Evidence map›Paper›PMID 40354465›Full record

ArticlePloS one2025

The protocol for a pilot feasibility trial of Improving Neurodevelopmental ouTcomes After prenatal Cannabinoid in uTero exposure (INTACT) study for a multi-center trial.

Jessie R Maxwell, Leigh-Anne Cioffredi, Maria M Talavera-Barber, Matthew Henry, Sandra Beauman, Anne Hittson, Meggie McCoy, Laurie Chassereau, Jing Jin, Preetha A Abraham and 3 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06423664 (Pilot Feasibility Trial of Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06423664 narecruitingnot on this map

Pilot Feasibility Trial of Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure (INTACT)

TypeinterventionalSponsorIDeA States Pediatric Clinical Trials NetworkRan2025 to 2026Enrolled20ConditionsDevelopmental DelayArmsPlay and Learn Strategies (PALS) Program
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jessie R MaxwellDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico, United States of America.ORCID https://orcid.org/0000-0001-8990-7239
Leigh-Anne CioffrediDepartment of Pediatrics, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.
Maria M Talavera-BarberAvera Research Institute, Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, United States of America.ORCID https://orcid.org/0000-0002-5290-1375
Matthew HenryECHO ISPCTN Data Coordinating and Operations Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Sandra BeaumanDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico, United States of America.
Anne HittsonDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico, United States of America.
Meggie McCoyAvera Research Institute, Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, United States of America.
Laurie ChassereauDepartment of Pediatrics, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.
Jing JinDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Preetha A AbrahamEnvironmental Influences on Child, Health Outcomes (ECHO) Program Institutional Development Award (IDeA) States Pediatric Clinical Trials Network, NIH, Rockville, Maryland, United States of America.
Linda Y FuEnvironmental Influences on Child, Health Outcomes (ECHO) Program Institutional Development Award (IDeA) States Pediatric Clinical Trials Network, NIH, Rockville, Maryland, United States of America.
Hengameh RaissyDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico, United States of America.
Jessica N SnowdenDepartment of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

Funding

IMproving Pediatric Access to Clinical Trials in Vermont (IMPACT VT)UG1OD024955 · OD · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Kelly Jean Cowan, Leslie W Young · 2016 to 2026
$4.8M
South Dakota Pediatric Clinical Trials Network (SoDakPCTN)UG1OD030019 · OD · AVERA MCKENNAN · PI Jyoti Angal, Maria M Barber · 2020 to 2026
$2.6M
NIH HHS UG1 OD024955NIH HHS UG1 OD030019
6 · The paper itself

Abstract

backgroundLegalization of recreational cannabis use is expanding across the United States, and prenatal cannabis has steadily increased. Evidence suggests that many pregnant individuals use cannabis to relieve symptoms like nausea. Research has demonstrated an association between prenatal cannabinoid exposure and infant deficits in attention, planning, and memory. In other high-risk populations, interventions aimed at increasing parental responsiveness have improved cognitive functioning in the children. This pilot trial aims to utilize a contingent responding training program in birthing parent-infant dyads with prenatal cannabinoid exposure to assess the feasibility of recruitment, completion of the proposed intervention and adherence.

methodsThis study will enroll post-partum birthing parents who used cannabinoid products during pregnancy at three clinical sites. After consenting and confirming eligibility, birthing parents will be oriented to the online program Play and Learning Strategies (ePALS) by the study team member, after which they will complete asynchronous monthly modules for 12 months that highlight aspects of contingent responding. Study staff at each site will be trained as coaches, meeting monthly with the birthing parent to review and reinforce the areas of focus. The primary objectives of the study will focus on the ability to recruit eligible birthing caregivers with cannabinoid use during pregnancy, the ability to retain participants for the intervention duration as measured through completion of the study session when the child is 12 months of age, and to assess the overall participant adherence of monthly sessions. DISCUSSION: As cannabinoid use during pregnancy becomes more prevalent, it is critical that we can provide interventions to optimize infant developmental outcomes. This pilot trial is focused on adapting a proven intervention used in other high-risk populations to determine if it can be applied to this population. If successful, a future trial would focus on the efficacy of this intervention following prenatal cannabinoid exposure.

trial registrationClinicaltrials.gov NCT06423664.

Indexed as

CannabinoidsNeurodevelopmental DisordersPrenatal Exposure Delayed EffectsAdultFeasibility StudiesFemaleHumansInfantMaleMulticenter Studies as TopicParentsPilot ProjectsPregnancyCannabinoids

Identifiers

PMID40354465
PMCPMC12068654

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.